跳至主要内容
临床试验/NCT01758081
NCT01758081进行中(未招募)不适用

Effects of Vitamin D and Omega-3 Fatty Acids on Infectious Diseases and hCAP18

Brigham and Women's Hospital1 个研究点 分布在 1 个国家目标入组 25,874 人开始时间: 2010年7月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
25,874
试验地点
1
主要终点
upper respiratory infection

研究概览

简要总结

The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is an ongoing randomized clinical trial in 25,875 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor® fish oil, 1 gram) reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses. This ancillary study is being conducted among participants in VITAL and will examine whether vitamin D or omega-3 fatty acids affect risk of infection and plasma hCAP18 levels.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Factorial
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
50 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

vitamin D + fish oil

Active Comparator

vitamin D3 + Omacor

干预措施: vitamin D3 (Dietary Supplement)

vitamin D + fish oil

Active Comparator

vitamin D3 + Omacor

干预措施: omega-3 fatty acids (fish oil) (Drug)

vitamin D + fish oil placebo

Active Comparator

vitamin D3 + fish oil placebo

干预措施: vitamin D3 (Dietary Supplement)

vitamin D + fish oil placebo

Active Comparator

vitamin D3 + fish oil placebo

干预措施: fish oil placebo (Dietary Supplement)

vitamin D placebo + fish oil

Active Comparator

vitamin D placebo + Omacor

干预措施: omega-3 fatty acids (fish oil) (Drug)

vitamin D placebo + fish oil

Active Comparator

vitamin D placebo + Omacor

干预措施: Vitamin D3 placebo (Dietary Supplement)

vitamin D placebo + fish oil placebo

Placebo Comparator

vitamin D placebo + fish oil placebo

干预措施: Vitamin D3 placebo (Dietary Supplement)

vitamin D placebo + fish oil placebo

Placebo Comparator

vitamin D placebo + fish oil placebo

干预措施: fish oil placebo (Dietary Supplement)

结局指标

主要结局

upper respiratory infection

时间窗: one year

hCAP-18

时间窗: one year

次要结局

  • lower respiratory infection(5 years)
  • urinary tract infection(5 years)
  • cellulitis(5 years)
  • antimicrobial-treated infection(5 years)
  • infection-related hospitalizations(5 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Carlos A. Camargo

Professor of Medicine

Brigham and Women's Hospital

研究点 (1)

Loading locations...

相似试验

Effects of Vitamin D and Omega-3 Fatty Acids on... | 临床试验